What should I do if I become drug-resistant after taking Eculizumab?

Eculizumab (Eculizumab) is a recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). If a patient becomes resistant to eculizumab, they should inform their doctor immediately. They will evaluate the patient's condition and may perform some tests to determine if drug resistance is indeed occurring, as each person's body is different and responds differently to drug resistance.

If drug resistance is confirmed, doctors will develop new treatment plans based on the specific situation. When faced with drug resistance, doctors may consider increasing or decreasing the dose of eculizumab to see if the drug resistance can be improved; they may also combine it with other drugs or treatments to increase the therapeutic effect, such as other types of immune inhibitors or biological agents. In some cases, your doctor may recommend stopping eculizumab and treating with another appropriate medication.

The generic drug Eculizumab has been launched in China and is covered by medical insurance. It is only available for reimbursement to eligible patients. The specification is 300mg (30ml) and the price per box may be more than 3,000 yuan. It is understood that the price of each box of the original Eculizumab drug sold overseas is more than 6,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold at home and abroad are basically the same, and the price of the original drug is still relatively expensive. There are currently no generic versions of eculizumab available on the market.